Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01175980 · OUTCOME

Response Duration (RD)

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma · Source last updated 2020-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months

What was measured

Median point estimate and full range will be documented, since only two patients achieved a response.

Analysis population: Only 2 patients achieved a response.

Groups in this outcome

Treatment (Vorinostat)

Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Vorinostat)2

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Treatment (Vorinostat)30.1Not reported7.253.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        7.2
        upper Limit
        53.0
        value
        30.1
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
Median point estimate and full range will be documented, since only two patients achieved a response.
dispersion Type
Full Range
groups
  1. description
    Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO
    id
    OG000
    title
    Treatment (Vorinostat)
param Type
MEDIAN
population Description
Only 2 patients achieved a response.
reporting Status
POSTED
time Frame
From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months
title
Response Duration (RD)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice